Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Ebola Surging Where it Had Been Beaten Back

September 8, 2014 10:30 am | by Boubacar Diallo and Sarah DiLorenzo | News | Comments

Doctors Without Borders shuttered one of its Ebola treatment centers in Guinea in May, thinking the virus was being contained there. The Macenta region, right on the Liberian border, had been one of the first places where the outbreak surfaced, but they hadn't seen a new case for weeks. Now, months later, Macenta is once again a hotspot. Read more...

TOPICS:

Ascendia Advances Nano-Emulsion Technology Platform with ASD-002 Program

September 5, 2014 3:06 pm | News | Comments

Ascendia Pharmaceuticals announced that the company has successfully applied its nano-emulsion technology platform to a novel injectable formulation of clopidogrel- the world’s top-selling blood thinner medicine. Read more...       

TOPICS:

Soligenix Acquires Phase-3-Ready Oncology Program

September 5, 2014 2:58 pm | News | Comments

Soligenix Inc. announced the acquisition of a novel orphan drug candidate, known as SGX301, which is poised to enter pivotal Phase 3 clinical testing for the treatment of cutaneous T-cell lymphoma and is highly synergistic with the company’s existing development pipeline. Read more...

TOPICS:
Advertisement

FDA Lifts Partial Hold on OncoMed's Cancer Drug

September 5, 2014 2:52 pm | News | Comments

OncoMed Pharmaceuticals announced that the FDA removed the partial clinical hold on the company's ipafricept (FZD8-Fc, OMP-54F28) Phase 1 clinical trials. Read more...                        

TOPICS:

U.S. in Danger of Losing Biotech Edge, Experts Say

September 5, 2014 2:48 pm | News | Comments

The United States is in danger of losing its biomedical edge to countries that are aggressively funding research into personalized medicine, according to experts in the field. Read more...

TOPICS:

WHO Backs Use of Survivors' Blood as Ebola Treatment

September 5, 2014 2:42 pm | News | Comments

The World Health Organization recommends that doctors should use blood from survivors to treat patients in an effort to combat the biggest-ever outbreak of Ebola. Read more...                      

TOPICS:

Newly Approved Kidney Drug Gets Unexpected Safety Warning

September 5, 2014 2:34 pm | News | Comments

Keryx Biopharmaceuticals received approval Friday for a pill to treat complications of kidney disease in dialysis patients, but the company's stock fell as investors reacted to an unexpected safety warning in the drug's prescribing label. Read more...

TOPICS:

NeuroDerm Starts Phase 2a Study of Parkinson’s Drug

September 5, 2014 11:11 am | News | Comments

NeuroDerm Ltd. announced that the first patients with severe Parkinson’s disease have been enrolled and dosed in a Phase 2a trial of ND0612H, a high-dose form of NeuroDerm’s proprietary liquid levodopa/carbidopa (LD/CD) drug formulation. Read more...

TOPICS:
Advertisement

Antisense Acromegaly Drug Shows Efficacy in Phase 2

September 5, 2014 11:04 am | News | Comments

Antisense Therapeutics Ltd. reported the primary efficacy results from its Phase 2 clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. Read more...               

TOPICS:

Flu Vaccine Protects Mothers, Babies

September 5, 2014 10:53 am | News | Comments

A new study shows that the influenza vaccination of pregnant HIV-uninfected and HIV-infected women is safe and protects the women against confirmed influenza illness. Read more...                     

TOPICS:

Actavis Antibiotic NDA Accepted, Deemed QIDP

September 5, 2014 10:27 am | News | Comments

Actavis plc confirmed that the FDA has accepted for filing Actavis' application for ceftazidime-avibactam, its investigational antibiotic for the treatment of patients with Complicated Urinary Tract Infections and Complicated Intra-Abdominal Infections. Read more...

TOPICS:

U.S. to Give $75M to Expand Ebola Care Centers

September 5, 2014 10:19 am | by Jonathan Paye-Layleh and Sarah DiLorenzo | News | Comments

The American aid agency announced Thursday it would donate $75 million to fund 1,000 more beds in Ebola treatment centers in Liberia and buy 130,000 more protective suits for health care workers. Read more...            

TOPICS:

FDA OKs Merck Cancer Drug, 1st in New Class

September 5, 2014 8:29 am | by Linda A. Johnson, AP Business Writer | News | Comments

Merck & Co. on Thursday won the first U.S. approval for a new kind of cancer drug with big advantages over chemotherapy and other older cancer treatments. Read more...                       

TOPICS:

FDA Puts Merck's Relebactam on Fast Track as QIDP

September 4, 2014 2:57 pm | News | Comments

Merck announced that the FDA has designated relebactam, the company’s investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status. Read more...            

TOPICS:

Mallinckrodt's Pain Drug Shows Efficacy in Phase 3

September 4, 2014 2:52 pm | News | Comments

Mallinckrodt reported that a Phase 3 efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy. Read more...            

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading